Pharming Group N.V. (PHAR) Earnings History
Earnings Pressure21 years of earnings data (2005–2025) · 5-year EPS trend is negative
Loading earnings history...
Pharming Group N.V. (PHAR) Earnings Overview
As of June 28, 2026, Pharming Group N.V. (PHAR) reported trailing twelve-month net income of $5.31B, reflecting +123.5% year-over-year growth. The company earned $75.66 per diluted share over the past four quarters, with a net profit margin of 0.8%.
Looking at the long-term picture, PHAR's 5-year EPS compound annual growth rate (CAGR) stands at -38.9%, signaling declining earnings. The company achieved its highest annual net income of $41M in fiscal 2019.
Pharming Group N.V. maintains positive profitability with a gross margin of 87.9%, operating margin of 5.1%, and net margin of 0.8%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including LGND ($154M net income, 46.4% margin), RARE (-$609M net income, -85.4% margin), ACAD ($376M net income, 36.5% margin), PHAR has room to improve margins relative to the peer group. Compare PHAR vs LGND →
PHAR Earnings vs Peers
Earnings metrics vs comparable public companies
PHAR Historical Earnings Data (2005–2025)
21 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3M | +124.1% | $19M | $0.04 | 0.8% | 5.1% |
| 2024 | -$12M | -12.3% | -$9M | $-0.17 | -4.0% | -2.9% |
| 2023 | -$11M | -177.1% | -$5M | $-0.14 | -4.3% | -2.2% |
| 2022 | $14M | -14.5% | $18M | $0.16 | 6.7% | 8.9% |
| 2021 | $16M | -57.6% | $14M | $0.18 | 8.0% | 6.8% |
| 2020 | $38M | -6.9% | $76M | $0.47 | 17.8% | 35.9% |
| 2019 | $41M | +41.9% | $68M | $0.48 | 21.4% | 36.0% |
| 2018 | $29M | +129.8% | $43M | $0.35 | 18.5% | 28.1% |
| 2017 | -$96M | -420.1% | $26M | $-1.54 | -89.2% | 24.4% |
| 2016 | -$18M | -69.4% | -$12M | $-0.35 | -110.5% | -72.7% |
| 2015 | -$11M | -55.2% | -$14M | $-0.22 | -92.0% | -118.5% |
| 2014 | -$7M | +66.3% | $3M | $-0.14 | -27.2% | 13.6% |
| 2013 | -$21M | +34.7% | -$10M | $-0.45 | -220.0% | -101.0% |
| 2012 | -$32M | -43.7% | -$23M | $-3.46 | -227.0% | -164.5% |
| 2011 | -$22M | +70.4% | -$24M | $-3.74 | -570.3% | -616.9% |
| 2010 | -$75M | -63.2% | -$59M | $-22.35 | -9837.2% | -7701.7% |
| 2009 | -$46M | -25.9% | -$40M | $-31.39 | -2925.2% | -2540.9% |
| 2008 | -$36M | +29.7% | -$41M | $-31.60 | -3946.5% | -4437.8% |
| 2007 | -$52M | -112.7% | -$36M | $-45.35 | -5161.2% | -3568.3% |
| 2006 | -$24M | -15.4% | -$24M | $-22.50 | -12582.4% | -12267.4% |
| 2005 | -$21M | - | -$22M | $-21.21 | -4409.6% | -4553.3% |
Download Data
Export PHAR earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
21+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PHAR — Frequently Asked Questions
Quick answers to the most common questions about buying PHAR stock.
What is PHAR earnings per share (EPS)?
PHAR trailing twelve-month (TTM) diluted EPS is $75.66, reflecting +123.5% year-over-year growth. The 5-year EPS CAGR is -38.9%. Complete EPS history from 2005 to 2025 is available in the table on this page.
What is Pharming Group N.V.'s net income?
Pharming Group N.V. (PHAR) trailing twelve-month net income is $5.3B as of 2025. Earnings grew +123.5% year-over-year.
Is PHAR profitable?
Yes, PHAR is profitable with a TTM net income of $5.3B and a net profit margin of +0.8%.
What is PHAR's earnings growth rate?
PHAR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: -37.0%, 5-Year: -38.9%, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2005 to 2025.
What are PHAR's profit margins?
Pharming Group N.V. net profit margin is +0.8%, operating margin is +5.1%, and gross margin is +87.9%. Below-average margins reflect competitive or cost pressures. Return on Equity is +1.1%.
Is PHAR growing earnings?
Yes, PHAR earnings are accelerating — EPS growth of +123.5% exceeds the 5-year CAGR of -38.9%. TTM net income reached $5.3B. Earnings momentum is strengthening.
What was PHAR's best earnings year?
Pharming Group N.V.'s highest annual net income on record is $41M, achieved in fiscal year 2019. Earnings history on this page spans 2005 to 2025 and includes all annual and quarterly figures.
What were PHAR's earnings last quarter?
PHAR's most recent reported quarter was Q1 2026. Net income was $-5M with diluted EPS of $-0.07. For a full breakdown of all quarters, see the quarterly earnings table on this page.